Fujitsu, Kyoto University, and Chordia Therapeutics launch AI trials to discover biomarkers for new cancer drugs
TOKYO, May 17, 2023 - (JCN Newswire via SEAPRWire.com) - Fujitsu Limited, Kyoto University (1), Chordia Therapeutics, Inc. (2), today announced the beginning of field trials leveraging Fujitsu's AI causal discovery technology to shed light on biomarkers (3) that increase the probability of success or shorten the duration of clinical trials in the development of new cancer drugs.Using results obtained from Kyoto University's next-generation sequencer (4) platform for analyzing genomic information and Fujitsu's causal discovery technology on its "Fujitsu Kozuchi (code name) - Fujitsu AI Platform" where advanced AI technologies can be rapidly tested, this project will comprehensively investigate causal structures and the conditions under which these structures occur in the drug effect and the estimated 20,000 genes that compose the human genome. This information will assist researchers working to discover biomarkers for patient stratification that can be used to determine the efficacy of cancer treatments that target RNA regulatory stress (5), under development by Kyoto University and Chordia since May 2018.Through this demonstration, Fujitsu, Kyoto University, and Chordia Therapeutic...
